Stockreport

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF 24 Week post-treatment follow-up data in chronic hepatitis B from MARCH Phase 2 study to be shared in oral presentation SAN FRANCISCO, April 24, 2025 BUSINESS WIRE )- [Read more]